Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain
- Registration Number
- NCT02262676
- Lead Sponsor
- Bayer
- Brief Summary
Depict demographic and clinical features of patients with atrial fibrillation treated with rivaroxaban to prevent stroke and pulmonary embolism in routine clinical practice
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2251
Inclusion Criteria
- Patients ≥ 18 years
- Patients with atrial fibrillation
- Patients in treatment with rivaroxaban for stroke prevention in atrial fibrillation at least 3 months previous to inclusion period in study
Read More
Exclusion Criteria
- Patients in treatment after start of study
- Patients treated with other anticoagulant treatment
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Rivaroxaban Rivaroxaban (Xarelto, BAY59-7939) Patients with Atrial fibrillation treated with Rivaroxaban
- Primary Outcome Measures
Name Time Method Medical History At recruitment visit Demographic Data At recruitment visit
- Secondary Outcome Measures
Name Time Method Assess the quality of life in patients At recruitment visit By use of Short-Form 12 Health Survey,version 2 (SF12v2) questionnaire
Assess regional differences among the different Spanish autonomous communities on the management of patients with rivaroxaban treatment during the routine clinical practice At recruitment visit By use of Informe de Posicionamiento Terapéutico (Spanish Questionnaire)
Adherence to rivaroxaban treatment At recruitment visit By use of Morisky-Green questionnaire
Assess the satisfaction of rivaroxaban treatment At recruitment visit By use of Anti-Clot Treatment Scale (ACTS) questionnaire